TY - JOUR
T1 - Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals
T2 - a randomised controlled trial
AU - Juel, Caroline Trunk-Black
AU - Lund, Asger B.
AU - Haedersdal, Sofie
AU - Andersen, Maria M.
AU - Hansen, Carsten P.
AU - Storkholm, Jan H.
AU - van Hall, Gerrit
AU - Hartmann, Bolette
AU - Rosenkilde, Mette M.
AU - Kibsgaard, Camilla J.
AU - Dela, Flemming
AU - Albrechtsen, Nicolai J. Wewer
AU - Holst, Jens J.
AU - Vilsboll, Tina
AU - Knop, Filip K.
PY - 2025
Y1 - 2025
N2 - Aims/hypothesis: Previous studies have indicated that 29-amino-acid glucagon (i.e. 'pancreatic' glucagon) circulates in totally pancreatectomised individuals and that a postprandial glucagon response can be detected. Using a glucagon receptor antagonist (GRA), we investigated the possible role of extrapancreatic glucagon on glucose, lipid and amino acid metabolism in totally pancreatectomised individuals. Method: In a randomised, crossover study, nine totally pancreatectomised individuals and nine matched healthy control individuals were given, in randomised order (planned on the website www.random.org), 300 mg GRA (LY2409021; Eli Lilly) or placebo 10 h before two 3 h OGTTs. The experiment was double-masked (i.e. both participants and investigator were masked for the type of the experimental day [day A vs day B]). The key inclusion criteria for the healthy control participants were age >18 years, normal fasting plasma glucose and HbA(1c) 31-44 mmol/mol (6.0-7.2%), haemoglobin >7.0 mmol/l (men) / >6.5 mmol/l (women) and informed consent. Key inclusion criteria for the pancreatectomised individuals were age >18 years, haemoglobin in the normal range and informed consent. The primary endpoint was the difference in plasma glucose excursions between study days. Results: Glucagon concentrations remained unchanged from fasting concentrations during the OGTT in the totally pancreatectomised individuals on both study days and circulating glucose, lipids and amino acid levels were unaffected by treatment with LY2409021 compared with placebo. In the control group, LY2409021 resulted in relevant pharmacodynamic effects, including lower fasting plasma glucose (4.7 [0.1] vs 5.2 [0.1] mmol/l, p=0.001) and augmented concentrations of amino acids in plasma, compared with placebo. Conclusions/interpretation: We conclude that inhibition of the glucagon receptor using LY2409021 during OGTT in totally pancreatectomised individuals does not produce detectable effects on glucose, lipid or amino acid metabolism, ruling out metabolic effects of extrapancreatic glucagon.
AB - Aims/hypothesis: Previous studies have indicated that 29-amino-acid glucagon (i.e. 'pancreatic' glucagon) circulates in totally pancreatectomised individuals and that a postprandial glucagon response can be detected. Using a glucagon receptor antagonist (GRA), we investigated the possible role of extrapancreatic glucagon on glucose, lipid and amino acid metabolism in totally pancreatectomised individuals. Method: In a randomised, crossover study, nine totally pancreatectomised individuals and nine matched healthy control individuals were given, in randomised order (planned on the website www.random.org), 300 mg GRA (LY2409021; Eli Lilly) or placebo 10 h before two 3 h OGTTs. The experiment was double-masked (i.e. both participants and investigator were masked for the type of the experimental day [day A vs day B]). The key inclusion criteria for the healthy control participants were age >18 years, normal fasting plasma glucose and HbA(1c) 31-44 mmol/mol (6.0-7.2%), haemoglobin >7.0 mmol/l (men) / >6.5 mmol/l (women) and informed consent. Key inclusion criteria for the pancreatectomised individuals were age >18 years, haemoglobin in the normal range and informed consent. The primary endpoint was the difference in plasma glucose excursions between study days. Results: Glucagon concentrations remained unchanged from fasting concentrations during the OGTT in the totally pancreatectomised individuals on both study days and circulating glucose, lipids and amino acid levels were unaffected by treatment with LY2409021 compared with placebo. In the control group, LY2409021 resulted in relevant pharmacodynamic effects, including lower fasting plasma glucose (4.7 [0.1] vs 5.2 [0.1] mmol/l, p=0.001) and augmented concentrations of amino acids in plasma, compared with placebo. Conclusions/interpretation: We conclude that inhibition of the glucagon receptor using LY2409021 during OGTT in totally pancreatectomised individuals does not produce detectable effects on glucose, lipid or amino acid metabolism, ruling out metabolic effects of extrapancreatic glucagon.
KW - Glucagon
KW - Glucagon receptor antagonist
KW - Ly2409021
KW - Postprandial glucose excursions
KW - Total pancreatectomy
U2 - 10.1007/s00125-025-06534-z
DO - 10.1007/s00125-025-06534-z
M3 - Journal article
C2 - 40968190
SN - 0012-186X
VL - 68
SP - 2807
EP - 2822
JO - Diabetologia
JF - Diabetologia
ER -